Australia markets closed

Oragenics, Inc. (UAV.F)

Frankfurt - Frankfurt Delayed price. Currency in USD
Add to watchlist
0.0000-7.5960 (-100.00%)
As of 10:03AM CEST. Market open.
Full screen
Loading interactive chart…
  • GlobeNewswire

    Oragenics, Inc. Announces Pricing of Public Offering

    SARASOTA, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of 1,100,000 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $1.00 per share. The closing of the public offering is expected to occur on or about June 26, 2024

  • GlobeNewswire

    Oragenics, Inc. Announces Proposed Public Offering

    SARASOTA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof). All of the securities to be sold in the offering are to be offered by Oragenics. The offering is subject to market conditions, and there can be no assurance a

  • GlobeNewswire

    Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance

    SARASOTA, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated June 18, 2024, notifying the Company that it has accepted the Company’s plan to regain compliance with NYSE American’s continued listing standards. The NYSE American has reviewed Oragenic